ITCI - Intra-Cellular Therapies Q2 2023 Earnings Preview

2023-08-02 14:28:44 ET

• Intra-Cellular Therapies ( NASDAQ: ITCI ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.
• The consensus EPS Estimate is -$0.59 and the consensus Revenue Estimate is $106.81M (+92.1% Y/Y).
• Over the last 1 year, ITCI has beaten EPS estimates 25% of the time and has beaten revenue estimates 100% of the time.
• Over the last 3 months, EPS estimates have seen 6 upward revisions and 3 downward. Revenue estimates have seen 6 upward revisions and 4 downward.

For further details see: